Northwire Canada EditionFriday, October 16, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4170.10 +1.5% SILVER 57.16 +2.3% COPPER 6.56 −1.5% OIL 97.97 +3.0% PALLADIUM 1136.00 +3.6% LUN 32.91 +0.6% DLP 0.290 −3.3% VCV 0.065 −13.3% GG 2.89 +1.4% NBLC 0.015 +0.0% SF 0.300 −4.8% ATY 0.215 +2.4% GHL 0.060 −7.7% STND 0.060 −7.7% B 0.550 −3.5% HBM 34.33 −0.5% NTR 98.77 −0.7% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.175 −18.6% CLCH 1.08 −1.8% GOLD 4170.10 +1.5% SILVER 57.16 +2.3% COPPER 6.56 −1.5% OIL 97.97 +3.0% PALLADIUM 1136.00 +3.6% LUN 32.91 +0.6% DLP 0.290 −3.3% VCV 0.065 −13.3% GG 2.89 +1.4% NBLC 0.015 +0.0% SF 0.300 −4.8% ATY 0.215 +2.4% GHL 0.060 −7.7% STND 0.060 −7.7% B 0.550 −3.5% HBM 34.33 −0.5% NTR 98.77 −0.7% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.175 −18.6% CLCH 1.08 −1.8%
Financings

Mindbio increases placement to $1.5-million

By The Northwire Desk — AI Analysis Mar 19, 2026 · 18:05 MBIO · 1.02 Mindbio Therapeutics Corp
MBIO · Price

Executive Summary

  • Mindbio Therapeutics Corp. is upsizing its non-brokered private placement from $650,000 to up to $1.5 million.
  • The company intends to issue up to 2.5 million units at a price of $0.60 per unit, consisting of one common share and one share purchase warrant per unit.
  • Completion of the offering is subject to final board and regulatory approvals.

Key Details

  • Transaction Type: Upsize of non-brokered private placement.
  • Gross Proceeds: Up to $1.5 million (increased from previous $650,000).
  • Unit Price: $0.60 per unit.
  • Quantity: Up to 2.5 million units.
  • Unit Composition: Each unit consists of one common share and one share purchase warrant.
  • Warrant Terms:
    • Exercise Price: $0.80 per share.
    • Duration: 36 months following closing.
    • Accelerated Expiry: Triggered if the closing price of shares on the Canadian Securities Exchange exceeds $1.00 for 10 consecutive trading days.
  • Resale Restrictions: All securities are subject to a 4-month and 1-day hold period.
  • Finders' Fees: The company will pay finders' fees to eligible third parties who introduced subscribers.
  • Regulatory Status: Subject to final board and regulatory approvals.

Notable Quotes

  • None provided in the text.
Read the original news release →

More from Mindbio Therapeutics Corp

Jun 09, 2026 · 07:00

From failed psychedelics to unproven AI kiosks: MindBio bets its survival on voice analytics, but cash burn and dilution loom.

Production / Operations Jun 04, 2026 · 11:12

MindBio’s Voice AI Pivot Buys Time, But Cash Runway and Dilution Risk Keep the Stock in the Red Zone

Other May 15, 2026 · 08:30

MindBio's AI Pivot Masks Failed Drug Trial and Dilution Risk

Other May 14, 2026 · 08:30

MindBio Pivots from Failed Psychedelic Trial to AI Voice Detection Amidst Dilution Concerns

Other May 13, 2026 · 08:30

MindBio Pivots to AI Voice Tech After Clinical Setback; Dilution Risks Loom

Other May 11, 2026 · 08:45

MindBio Pivots from Clinical Failure to AI Voice Analytics, But Dilution Risks Loom

Other